Regeneron (REGN) - Quarterly EPS earnings growth

regeneron.com - graphic logo of issuer REGN

Regeneron Pharmaceuticals (REGN) minimizes risks through a broad spectrum of innovative drugs for severe pathologies. Tracking quarterly EPS growth confirms the effectiveness of this strategy, where the current metric equals 36.20. Stable cash flow from Eylea ensures financial stability, while the commercial success of Dupixent, combined with share buybacks and a new pipeline, creates powerful drivers for further development.

Regeneron (REGN) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for Regeneron (REGN)

Summary company analytics:Regeneron Pharmaceuticals
Manufactured product of regeneron.com

Quarterly EPS growth reflects the change in net income per share compared to the same period last year. By analyzing the volatility of the quarterly EPS figure, an investor assesses the effectiveness of business scaling. This metric is sensitive to operating profit and the number of shares outstanding. For Regeneron Pharmaceuticals (REGN), this growth is supported by the high margins of its blockbusters. Patent protection for these drugs guarantees a steady capital inflow and a sustainable increase in profitability.

Competing companies

IRTC (iRhythm) - Year-over-year net earnings per share growth for the last 12 months|Lantheus Medical Imaging - Year-over-year earnings per one share growth for the last 12 months|MLYS (Mineralys Corp) - Quarterly EPS earnings growth|HeartFlow, Inc. - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months KMTS (Kestra Medical)|ESPR - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth AMRN (Amarin Pharma)|Year-over-year earnings per share growth rate for the last twelve months AVR (Anteris Technologies Ltd)|Tenaya Therapeutics, Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months CVRx, Inc. CVRX|MIST (Milestone Pharmaceuticals Inc.) - Year-over-year net earnings per share growth for the last 12 months|Cardiol Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BEAT (HeartBeam Corporation) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Tenax Therapeutics Inc|Quarterly EPS earnings growth ADGM|BioCardia, Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth VTAK (Catheter Precision Inc)|ABIO - Year-over-year net earnings per share growth for the last 12 months|Acasti Pharma - Quarterly EPS earnings growth|AVTE - Quarterly EPS earnings growth|VERV (vervetx.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months WINT (Windtree Therapeutics Inc.)